Cogent Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2017 |
|---|---|
| Operating Activities | |
| Net Income | $-25.5M |
| Depreciation & Amortization | $1.2M |
| Depreciation | — |
| Amortization | — |
| Stock-Based Compensation | $1.3M |
| Net Cash from Operating Activities | $-25.8M |
| Investing Activities | |
| Capital Expenditures | $912.0K |
| Business Acquisitions | — |
| Net Cash from Investing Activities | $13.6M |
| Financing Activities | |
| Dividends Paid | — |
| Stock Repurchases | — |
| Net Cash from Financing Activities | $-729.0K |
| Net Change in Cash | $-13.0M |
| Free Cash Flow | $-26.7M |